期刊
AIDS
卷 24, 期 3, 页码 F11-F14出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0b013e328335749d
关键词
antiretrovial therapy; CD4; women
资金
- Canadian International Development Agency (CIDA) [690/M3688]
- United States Agency for International Development (USAID) [HRN-A-00-97-00015-00]
- Bill and Melinda Gates Foundation, Seattle Washington, USA
- SARA
- Department for International Development (DFID), United Kingdom [AG 4996]
Background: Whereas HAART initiated at CD4 cell counts 351-450 cells/mu l reduces mortality, compared with starting at lower CD4 levels, there is currently no evidence for the advantages of initiating treatment at CD4 cell counts greater than 450 cells/mu l. Methods: Mortality hazard, as a function of CD4 cell count, was estimated among postpartum HIV-positive women in Zimbabwe, using HIV-negative women as the reference group. Results: Mortality within 24 months postpartum was 54 times higher among women with CD4 cell counts less than 200 cells/mu l, fell to 5.4 times higher for those with CD4 cell counts 400-600 cells/mu l but fell little thereafter. For CD4 cell counts greater than 600 cells/mu l the hazard was 6.2 (95% confidence interval 3.2-11.9). Conclusion: Early HAART initiation for all HIV-positive pregnant women may benefit individual mothers and infants, and Simultaneously reduce Population HIV incidence. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据